Lv52
1378 积分 2024-06-06 加入
P227 MANATEE: GYM329 (RO7204239) in combination with Risdiplam treatment in patients with spinal muscular atrophy (SMA)
25天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
1个月前
已完结
Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types
1个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
1个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
1个月前
已关闭
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1个月前
已完结
Current status and future trends of the global burden of MASLD
1个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
1个月前
已关闭
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
1个月前
已完结
皖公网安备34019202002308
